Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SOT102

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim, Sotio

Drug class:

DNA replication inhibitor, CLDN18.2-targeted antibody-drug conjugate

Related drugs:

‹

›

CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2
CLDN18.2 expression	Lung Adenocarcinoma	CLDN18.2 expression	Lung Adenocarcinoma	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D
CLDN18.2 expression	Colon Cancer	CLDN18.2 expression	Colon Cancer	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D
CLDN18.2 expression	Hepatocellular Cancer	CLDN18.2 expression	Hepatocellular Cancer	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D